Roche's New Obesity Drug Shows Promising Phase II Results
Swiss pharmaceutical giant Roche announced positive results from a Phase II trial of its obesity drug CT-388, which showed significant weight loss. The company aims to advance to Phase III trials and challenge industry leaders Novo Nordisk and Eli Lilly in the rapidly growing obesity drug market.
Swiss pharmaceutical firm Roche revealed on Tuesday that its twofold injection drug, CT-388, aimed at battling obesity, marked impressive success in a Phase II clinical trial.
According to Roche's chief medical officer Levi Garraway, the results, characterized by substantial weight loss and a favorable safety profile, heighten optimism for the subsequent Phase III trials, scheduled for later this quarter.
With sights set on the bustling obesity drug sector, Roche's strategic acquisition of Carmot Therapeutics for $2.7 billion in 2023 fortifies its position against leading competitors like Novo Nordisk and Eli Lilly.
Advertisement
ALSO READ
-
Roche's Breakthrough in Multiple Sclerosis Treatment
-
Super Bowl Ads Spotlight Weight-Loss Drugs in Direct-to-Consumer Blitz
-
Star-Studded Super Bowl Ads Propel GLP-1 Weight-Loss Drugs into Spotlight
-
Global Health Shifts: Nipah Virus Case, Drug Price Wars, and South Carolina Measles Surge
-
Celebrity Power Boosts Direct-to-Consumer Drug Ads in Super Bowl Showcase
Google News